Algernon Pharmaceuticals Inc. (AGNPF)
USD 0.05
(3.65%)
USD 0.05
(3.65%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -125.08 Thousand CAD | 91.12% |
| 2022 | -1.4 Million CAD | 41.58% |
| 2021 | -2.41 Million CAD | 60.61% |
| 2020 | -6.12 Million CAD | -2845.65% |
| 2019 | -207.81 Thousand CAD | 83.39% |
| 2018 | -1.25 Million CAD | 10.16% |
| 2017 | -1.39 Million CAD | 12.84% |
| 2016 | -1.59 Million CAD | -14.14% |
| 2015 | -1.39 Million CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -74.16 Thousand CAD | 40.71% |
| 2024 Q3 | -609.52 Thousand CAD | -699.1% |
| 2024 Q2 | -76.27 Thousand CAD | -2.84% |
| 2023 FY | -125.08 Thousand CAD | 91.12% |
| 2023 Q3 | -434.23 Thousand CAD | -96.86% |
| 2023 Q2 | -220.58 Thousand CAD | 68.02% |
| 2023 Q4 | -125.08 Thousand CAD | 71.19% |
| 2023 Q1 | -689.69 Thousand CAD | 51.03% |
| 2022 Q4 | -1.4 Million CAD | -61.37% |
| 2022 FY | -1.4 Million CAD | 41.58% |
| 2022 Q3 | -872.84 Thousand CAD | 51.86% |
| 2022 Q2 | -1.81 Million CAD | 32.77% |
| 2022 Q1 | -2.69 Million CAD | -11.86% |
| 2021 FY | -2.41 Million CAD | 60.61% |
| 2021 Q1 | -2.64 Million CAD | 56.72% |
| 2021 Q3 | -3.28 Million CAD | -8.01% |
| 2021 Q2 | -3.04 Million CAD | -14.91% |
| 2021 Q4 | -2.41 Million CAD | 26.67% |
| 2020 Q3 | -8.38 Million CAD | -283.11% |
| 2020 Q4 | -6.12 Million CAD | 27.04% |
| 2020 FY | -6.12 Million CAD | -2845.65% |
| 2020 Q1 | -1.57 Million CAD | -658.47% |
| 2020 Q2 | -2.18 Million CAD | -38.94% |
| 2019 FY | -207.81 Thousand CAD | 83.39% |
| 2019 Q3 | -497.44 Thousand CAD | 52.53% |
| 2019 Q1 | -1.35 Million CAD | -8.62% |
| 2019 Q2 | -1.04 Million CAD | 22.89% |
| 2019 Q4 | -207.81 Thousand CAD | 58.22% |
| 2018 FY | -1.25 Million CAD | 10.16% |
| 2018 Q1 | -1.22 Million CAD | 12.27% |
| 2018 Q4 | -1.25 Million CAD | 2.27% |
| 2018 Q2 | -1.46 Million CAD | -19.65% |
| 2018 Q3 | -1.28 Million CAD | 12.42% |
| 2017 FY | -1.39 Million CAD | 12.84% |
| 2017 Q3 | -1.64 Million CAD | 14.38% |
| 2017 Q1 | -2.14 Million CAD | -33.95% |
| 2017 Q2 | -1.92 Million CAD | 10.24% |
| 2017 Q4 | -1.39 Million CAD | 15.33% |
| 2016 Q3 | -1.88 Million CAD | 19.41% |
| 2016 Q1 | -2.55 Million CAD | -82.39% |
| 2016 FY | -1.59 Million CAD | -14.14% |
| 2016 Q4 | -1.59 Million CAD | 15.4% |
| 2016 Q2 | -2.34 Million CAD | 8.22% |
| 2015 FY | -1.39 Million CAD | 0.0% |
| 2015 Q4 | -1.39 Million CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bioxytran, Inc. | 1.89 Million USD | 106.587% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 100.794% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 131.127% |
| SQZ Biotechnologies Company | -36.23 Million USD | 99.655% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 105.579% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 100.292% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 98.016% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 113.491% |
| Marizyme, Inc. | 18.56 Million USD | 100.674% |
| Genus plc | 190.6 Million USD | 100.066% |
| Pharming Group N.V. | 109.8 Million USD | 100.114% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 114.541% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 110.304% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 118.395% |
| ContraFect Corporation | -6.02 Million USD | 97.924% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 110.826% |
| IMV Inc. | 7.67 Million USD | 101.631% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 102.273% |
| ONE Bio Corp. | 9.04 Million USD | 101.384% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 100.966% |
| Mesoblast Limited | 55.85 Million USD | 100.224% |
| MultiCell Technologies, Inc. | 90.04 USD | 139021.59% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 100.409% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.988% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 120.098% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 112.413% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 103.038% |
| Biomind Labs Inc. | 711.4 Thousand USD | 117.583% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 106.256% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 100.977% |
| Skye Bioscience, Inc. | -5.72 Million USD | 97.814% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 134.774% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 105.595% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 189.472% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 192.904% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 102.215% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 729.612% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 82.958% |
| EV Biologics, Inc. | 1.36 Million USD | 109.144% |
| Q BioMed Inc. | 4.06 Million USD | 103.081% |
| GB Sciences, Inc. | 1.74 Million USD | 107.159% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 31.941% |
| CSL Limited | 10.52 Billion USD | 100.001% |
| Agentix Corp. | 37.63 Thousand USD | 432.399% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 100.207% |
| Enzolytics Inc. | 981.65 Thousand USD | 112.742% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | 6.45 Million USD | 101.939% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 81.416% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 105.681% |
| argenx SE | -2.02 Billion USD | 99.994% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 100.288% |
| HST Global, Inc. | 96.79 Thousand USD | 229.229% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 99.734% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 160.657% |
| Halberd Corporation | 144.72 Thousand USD | 186.432% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 101.769% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 98.585% |
| Zenith Capital Corp. | 10.06 Thousand USD | 1342.895% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 104.618% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 105.242% |
| AVAX Technologies, Inc. | -5.9 Million USD | 97.881% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 176.035% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -582.853% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 162.408% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | 105.742% |
| Helix BioMedix, Inc. | -2.57 Million USD | 95.133% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 100.617% |
| Kadimastem Ltd | -253.1 Thousand USD | 50.579% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 102.797% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 162.153% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -9448.473% |
| LadRx Corporation | -2.03 Million USD | 93.858% |
| Cell Source, Inc. | 9.23 Million USD | 101.355% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -512.921% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 119.693% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 119.693% |
| Affymax, Inc. | -5.59 Million USD | 97.765% |
| Mobile Lads Corp. | 484.23 Thousand USD | 125.832% |
| Itoco Inc. | 228.3 Thousand USD | 154.789% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 191.982% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 102.523% |
| International Stem Cell Corporation | 2.59 Million USD | 104.83% |
| CytoDyn Inc. | 20.26 Million USD | 100.617% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -19233.076% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -1249.594% |
| Qrons Inc. | 351.42 Thousand USD | 135.593% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 101.623% |
| SYBLEU INC | 473.71 Thousand USD | 126.405% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 49.89% |
| Rebus Holdings, Inc. | 305 Thousand USD | 141.011% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 102.806% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 300.415% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 105.735% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 103.643% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 101.462% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 116.19% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 89.993% |
| Neutra Corp. | 52.18 Thousand USD | 339.686% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 94.974% |
| PureTech Health plc | -167.19 Million USD | 99.925% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 48.926% |
| IXICO plc | -4.44 Million USD | 97.186% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 100.946% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 100.228% |
| CSL Limited | 10.52 Billion USD | 100.001% |
| Cellectis S.A. | -43.81 Million USD | 99.715% |